HUMA vs CBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 04, 2026

HUMA

46.2
AI Score
VS
HUMA Wins

CBIO

45.7
AI Score

Investment Advisor Scores

HUMA

46score
Recommendation
HOLD

CBIO

46score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric HUMA CBIO Winner
Forward P/E 35.8423 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth -4.3% 0.0% CBIO
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 46.2/100 45.7/100 HUMA
Profit Margin 0.0% 0.0% Tie
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

HUMA 1M: -2.9% · 3M: -19.4% CBIO 1M: -13.0% · 3M: -17.7%

Current Technical Phase

HUMA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 46.4 · Price: $0.69

CBIO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -9.2%), weak momentum, RSI 41

RSI (14): 41.2 · Price: $14.87

Fundamentals Snapshot

Metric HUMA CBIO
Market Cap
Forward P/E -2.9 -5.7
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin -40.5% 1.0%
Operating Margin -57.0% -14.3%
EPS -0.63 -0.14
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HUMA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.